Cell BioEngines, a clinical-stage biotechnology company developing a universal ‘plug-and-play’ allogeneic stem cell therapy platform and a portfolio of ‘off-the-shelf’ cell therapies for the treatment of hematologic and solid tumor malignancies, announced today that it has signed a new lab lease at the Center for Engineering and Precision Medicine (CEPM), launched by the Rensselaer Polytechnic Institute and the Icahn School of Medicine at Mount Sinai, starting May 1st. This new space will allow the Company to expand its internal R&D efforts by utilizing the cutting-edge resources that the CEPM facilities offer to further develop its platform technologies and advance its pipeline of innovative cell therapy product candidates. The decision to join the CEPM community builds upon the pre-existing relationship between the Company and Mount Sinai and further strengthens Cell BioEngines’ commitment to the New York City area.
Cell BioEngines Announces Establishment of New R&D Facility to Further Advance Its Platform and Pipeline of Innovative Cell Therapies
Not classified
